Item 2.02 Results of Operations and Financial Condition.

On November 10, 2021, VYNE Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2021. The press release is being furnished as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

Beginning on November 10, 2021, Company management will use the presentation attached as Exhibit 99.2 to this Current Report on Form 8-K in connection with investor meetings and industry conferences. In addition, slides 22 through 27 of the presentation will be discussed on today's earnings call.

The information in this Item 7.01 and Exhibit 99.2 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits


The following exhibits are being furnished herewith.




Exhibit No.            Description

  99.1                   Press Release, dated November 10, 2021.

  99.2                   Corporate Presentation.

104                    Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses